Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy.
The effects of indomethacin on urinary protein excretion, levels of serum albumin and renal function were studied prospectively in six patients with systemic lupus erythematosus (SLE) and refractory nephrotic syndrome due to lupus nephritis. Two had membranoproliferative glomerulonephritis, two had diffuse proliferative glomerulonephritis, and one each had mesangioproliferative and membranous glomerulonephritis. All experienced a considerable reduction in urinary protein excretion and an increase in serum albumin. Indomethacin was discontinued in two patients because of side effects, and proteinuria recurred to pretreatment levels. The decrease of proteinuria continued during long-term treatment in three patients. Indomethacin did not cause a permanent decline in renal function. Our results suggest that therapy with indomethacin may be beneficial for the treatment of refractory nephrotic syndrome in selected SLE patients. However, because of potential side effects the administration of indomethacin should be monitored closely.
Espinoza
L R
LR
Department of Medicine, Louisiana State University School of Medicine, New Oreleans.
Jara
L J
LJ
Martinez-Osuna
P
P
Silveira
L H
LH
Cuellar
M L
ML
Seleznick
M
M
D000328:Adult; D003404:Creatinine / Q000378:metabolism; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000503:physiopathology; D008181:Lupus Nephritis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy
D003404:Creatinine; D007213:Indomethacin